Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
Thirty patients with Parkinson's disease were treated for four weeks with levodopa combined with an inhibitor of extracerebral dopa decarboxylase, L-alpha-methyldopahydrazine (MK 486). The therapeutic results were compared with the effects of treatment of a group of 40 patients with levodopa alone. Patients treated with the combined therapy improved more rapidly, had less nausea and vomiting, and required a much smaller dose of levodopa than patients treated with levodopa by itself.
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D002230:Carbidopa